{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-023570","form_type":"8-K","ticker":"DRMA","cik":"0001853816","company_name":"Dermata Therapeutics, Inc.","filed_at":"2025-08-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.373112+00:00","generated_at":"2026-05-17T13:59:47.869335+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Dermata reports positive Phase 3 STAR-1 data, Q2 2025 cash $6.5M","bullets":["XYNGARI™ Phase 3 STAR-1 met all three co-primary endpoints with statistical significance at weeks 4 and 12.","Raised $8.8M gross proceeds in H1 2025; cash $6.5M at June 30, expected to fund operations into Q2 2026.","R&D expenses $0.6M in Q2 2025 vs $2.0M in Q2 2024, decrease due to STAR-1 completion.","G&A expenses $1.2M in Q2 2025 vs $0.9M in Q2 2024; increase from compliance and personnel costs."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-023570","json":"https://secwatch.observer/filing/0001641172-25-023570.json","markdown":"https://secwatch.observer/filing/0001641172-25-023570.md","text":"https://secwatch.observer/filing/0001641172-25-023570.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1853816/000164117225023570/0001641172-25-023570-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1853816/000164117225023570/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T13:59:47.869335+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}